Aligos Q2 Loss Narrows to $1.5M on $28M Licensing Revenue, Cash Runway Through Q4
ALGS is trading near its 52-week low of $3.98 (14% above the low).
Summary
Aligos reported a Q2 net loss of just $1.5M, a sharp improvement driven by $28M in licensing revenue from its pevifoscorvir sodium deal. Operating expenses rose to $29.7M as R&D spending ramped on the Phase 2 B-SUPREME trial. The company reiterated a cash runway only through Q4 2026, keeping the going-concern risk front and center. This follows the $25M upfront payment received in July and full enrollment of the HBV study. Topline data from that trial is now expected in late Q3 2027, with a $3M milestone payment due this quarter.
At the time of this announcement, ALGS was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3M. The 52-week trading range was $3.98 to $13.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.